In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In todays Pharmaceutical Executive Daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.
Mirum Pharmaceuticals has completed its $268 million acquisition of Bluejay Therapeutics, a move aimed at bolstering its rare disease pipeline and expanding long-term growth opportunities. The deal adds late-stage and early clinical assets focused on serious liver and rare conditions, reinforcing Mirum’s strategy of building depth beyond its marketed portfolio.
In a separate industry analysis, experts argue that data visualization remains a persistent blind spot across biotech organizations. Despite growing investment in analytics and AI, many companies continue to struggle with translating complex data into clear, decision-ready insights—limiting the strategic value of clinical, commercial, and operational datasets.
Meanwhile, a new report highlights growing debate around pediatric vaccine guidance, with many pediatricians aligning with recommendations from the American Academy of Pediatrics and the CDC. The discussion underscores continued tensions between public health guidance, physician perspectives, and shifting policy narratives around vaccination.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
